James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

The study discovered information regarding how the PD-L1 pathway is regulated by the tumor suppressor gene p53, Welsh explains. However, researchers have had trouble understanding how to target the mutation. The study showed that p53 regulates PD-L1 expression through miR-34a.

Understanding more of the mechanisms behind the pathway may open up new therapy options for patients, he adds. Welsh expects additional solid tumors to be treated with PD-1 or PD-L1 agents in the near future.

View more from the 2015 AACR Annual Meeting

James Welsh, MD

Articles

Dr. Welsh on New Understanding of Regulating PD-L1 Expression